Loading...
Found 594 results for IU Health Enterprise System
A listing of IU Health Enterprise System medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
R
Rohan Maniar
What is the purpose of this study?This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC …
FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations
T
Tareq Salous
This is an open-label, multi-center, phase 1a/b study in participants with FGFR3-altered advanced solid tumors, including metastatic urothelial cancer (UC). The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that …
A Prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with Tivdak® in Recurrent or Metastatic Cervical Cancer
S
Sharon E. Robertson
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to …
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
U
Utpal Dave, MD
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Usual treatment after a complete response may include observation or high dose chemotherapy followed by …
A Randomized Phase Ii/Iii Study of Docetaxel and Ramucirumab with or Without Cemiplimab (Regn2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage Iv or Recurrent Non-Small Cell Lung Cancer (Lung-Map Non-Matched Sub-Study)
R
Rohan Maniar
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody …
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of Tng462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with Mtap Loss and Ras Mutation
A
Anita Turk, MD
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with the following agents: RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab-paclitaxel. Overall, the study comprises a dose escalation phase and a dose expansion phase.Interested in participating? For …
An Open-Label, Randomized Study of Bms-986489 (Atigotatug + Nivolumab Fixed-Dose Combination) Vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (Tigos-Ls)
M
Misty D. Shields, MD, PhD
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:Evaluate the efficacy of BMS-986489 vs durvalumabEvaluate the safety profile of BMS-986489Interested in participating? For more information about this research study or …
A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (Insight)
R
Rohan Maniar
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells …
Forager-2: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an Fgfr3 Genetic Alteration.
T
Tareq Salous
This phase II clinical trial tests how well pembrolizumab plus enfortumab vedotin prior to and after radical nephroureterectomy works in treating patients with high-risk upper tract urothelial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability …
A Randomized, Active-Controlled, Double-Blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with Folfox Versus Bevacizumab in Combination with Folfox for the First-Line Treatment of Metastatic Colorectal Cancer
A
Anita Turk, MD
Primary ObjectiveTo compare the progression-free survival (PFS) as assessed by blinded Independent. Radiological Review Committee (IRRC) based on Response Evaluation Criteria in. Solid Tumors (RECIST) v1.1, of ivonescimab in combination with modified 5-FU, oxaliplatin, and leucovorin (mFOLFOX6) to bevacizumab in combination with mFOLFOX6.Secondary ObjectivesTo compare the overall survival (OS) of …
Please choose between Voice or SMS based delivery of verification code
or